SCHEDULE: Third Rock Ventures Cuts Tango Therapeutics Stake

Third Rock Ventures has significantly reduced its beneficial ownership in Tango Therapeutics, Inc. to 6.97% through multiple open market dispositions.

Summary

• Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13D.
• The filing reports a decrease of over one percent (1%) in the aggregate beneficial ownership of Tango Therapeutics, Inc. common stock by the Reporting Persons.
• As of November 11, 2025, the Reporting Persons collectively hold 9,374,574 shares, representing approximately 6.97% of the Issuer's outstanding common stock.
• This percentage is calculated based on 134,593,998 shares of common stock issued and outstanding as of October 28, 2025, as disclosed in the Issuer's 10-Q filed on November 4, 2025.
• The decrease resulted from multiple open market dispositions totaling 5,352,942 shares between September 16, 2025, and November 12, 2025.
• Sale prices for these dispositions ranged from a weighted average of $7.04 to $10.15 per share.

Sentiment

Score: 3

Explanation: The significant reduction in ownership by a major institutional investor is generally a negative signal, indicating a potential loss of confidence or strategic rebalancing. While not catastrophic, it's a bearish indicator.

Negatives

• Third Rock Ventures, a significant institutional investor, has reduced its stake in Tango Therapeutics by over 1% (specifically, from approximately 10.94% to 6.97%), indicating a decrease in conviction or a portfolio rebalancing.
• The disposition of 5,352,942 shares over a period of less than two months could exert downward pressure on the stock price.
• The sales occurred at various price points, including a significant block of 1,512,000 shares sold at $8.20 on November 12, 2025.

Risks

• A significant reduction in beneficial ownership by a major institutional investor may signal a loss of confidence or a strategic shift by the investor.
• Large-scale selling by an insider or major shareholder can create negative market sentiment and potentially depress the stock price.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing reflects a significant institutional investor's decision to reduce its exposure to Tango Therapeutics. In the biotechnology sector, such moves by prominent venture capital firms can be closely watched as they may signal evolving perspectives on a company's pipeline, market position, or overall sector outlook. It could also simply be a portfolio rebalancing decision.

Comparison to Industry Standards

• A reduction in stake by a major venture capital firm like Third Rock Ventures, which specializes in life sciences, is often viewed by the market as a negative signal, similar to how other biotech-focused VCs (e.g., Flagship Pioneering, OrbiMed) manage their portfolio companies.
• While not directly comparable to specific projects, the timing of sales at varying price points (some higher, some lower) suggests a strategic exit or profit-taking rather than a single event. This is a common practice for venture funds as companies mature or reach certain valuation milestones.
• The decrease of nearly 4% in ownership (from approximately 10.94% to 6.97%) is substantial and would typically be scrutinized by investors comparing it to similar insider/major shareholder activity in other clinical-stage biotech companies.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by a major investor as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.
• Company Management: May face questions regarding the reasons for the significant investor's reduced stake and its implications for future funding or strategic direction.

Key Dates

Recommendation

The substantial reduction in stake by Third Rock Ventures, a prominent life sciences investor, signals a potential loss of confidence or a strategic exit. Such a move by a major shareholder often precedes or accompanies negative market sentiment and can put downward pressure on the stock price. Investors should consider this a bearish indicator and evaluate their positions accordingly, potentially reducing exposure.

Keywords

Tango Therapeutics, Third Rock Ventures, Schedule 13D, Beneficial Ownership, Stock Sales, Institutional Investor, Biotechnology, SEC Filing, Equity Stake, Share Disposition